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Abstract
Introduction: Because 30% of cigarettes sold in the United States are characterized as menthol cig-
arettes, it is important to understand how menthol preference may affect the impact of a nicotine 
reduction policy.
Methods: In a recent trial, non-treatment-seeking smokers were randomly assigned to receive 
very low nicotine cigarettes (VLNC; 0.4 mg nicotine/g tobacco) or normal nicotine cigarettes (NNC; 
15.5 mg/g) for 20 weeks. On the basis of preference, participants received menthol or non-menthol 
cigarettes. We conducted multivariable regression analyses to examine whether menthol prefer-
ence moderated the effects of nicotine content on cigarettes per day (CPD), breath carbon mon-
oxide (CO), urinary total nicotine equivalents (TNE), urinary 2-cyanoethylmercapturic acid (CEMA), 
and abstinence.
Results: At baseline, menthol smokers (n = 346) reported smoking fewer CPD (14.9 vs. 19.2) and 
had lower TNE (52.8 vs. 71.6 nmol/mg) and CO (17.7 vs. 20.5 ppm) levels than non-menthol smokers 
(n = 406; ps < .05). At week 20, significant interactions indicated that menthol smokers had smaller 
treatment effects than non-menthol smokers for CPD (–6.4 vs. –9.3), TNE (ratio of geometric means, 
0.22 vs. 0.10) and CEMA (ratio, 0.56 vs. 0.37; ps < .05), and trended toward a smaller treatment 
effect for CO (–4.5 vs. –7.3 ppm; p =  .06). Odds ratios for abstinence at week 20 were 1.88 (95% 
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confidence interval [CI] = 0.8 to 4.4) for menthol and 9.11 (95% CI = 3.3 to 25.2) for non-menthol 
VLNC smokers (p = .02) relative to the NNC condition.
Conclusions: Although menthol smokers experienced reductions in smoking, toxicant exposure, 
and increases in quitting when using VLNC cigarettes, the magnitude of change was smaller than 
that observed for non-menthol smokers.
Implications: Results of this analysis suggest that smokers of menthol cigarettes may respond to 
a nicotine reduction policy with smaller reductions in smoking rates and toxicant exposure than 
would smokers of non-menthol cigarettes.
Introduction
The Food and Drug Administration (FDA) recently announced a 
tobacco control framework focused on reducing the addictiveness 
of cigarettes as a means of reducing the public health burden of 
smoking in the United States.1 A mandated reduction in the nicotine 
content of all commercially available cigarettes to a minimally ad-
dictive level is the foundation of this framework. Data from several 
clinical trials provide evidence to support a nicotine reduction policy 
as a viable public health approach, with studies reporting reductions 
in cigarette smoking, toxicant exposure, and nicotine dependence, as 
well as increases in spontaneous quit attempts.2–9 A policy simulation 
estimated that approximately 5 million smokers would quit within 
the first year of an FDA-mandated low-nicotine product standard 
for cigarettes and would likely result in 16 million fewer people 
initiating smoking and 2.8 million fewer tobacco-related deaths by 
2060.10 Given these findings, the FDA issued an Advance Notice 
of Proposed Rulemaking in March 2018 regarding a low-nicotine 
product standard for cigarettes, signaling its interest in moving 
forward with this regulatory action.
Cigarettes containing menthol as a characterizing flavor com-
prise approximately 30% of the US cigarette market share and 
are disproportionately used by racial/ethnic minorities, sexual and 
gender minorities, adolescents, young adults, and individuals with 
psychiatric disorders.11–18 In 2017, over 34 million people in the 
United States smoked cigarettes.19 Thus, a low-nicotine product 
standard for cigarettes would affect upward of 10 million menthol 
cigarette smokers. Yet, previous trials of very low nicotine content 
(VLNC) cigarettes have not consistently or extensively reported trial 
outcomes by menthol smoking status, so relatively little is known 
about how menthol flavoring will affect the effects of cigarette nico-
tine reduction. Preclinical research indicates that menthol flavoring 
contributes to nicotine reinforcement and self-administration.20–23 
A  laboratory assessment of research cigarettes varying in nico-
tine content reported that menthol smokers required higher doses 
for discriminating nicotine in cigarettes compared to non-menthol 
smokers, suggesting that they are less sensitive to differences in nico-
tine content.24 Together, these studies suggest that menthol smokers 
could potentially be less sensitive to the effects of cigarette nicotine 
content on smoking behavior. However, no clinical trials have dir-
ectly examined this question.
Recently, a 20-week trial was conducted to determine the op-
timal approach for implementing a low-nicotine product standard 
for cigarettes (ie, immediate vs. gradual reduction in nicotine con-
tent).9 Results of that study indicated that immediate reduction led 
to significantly greater decreases in biomarkers of smoke exposure 
compared to the gradual reduction and control conditions. The pur-
pose of the current secondary analysis is to compare outcomes from 
that trial by menthol smoking status among participants assigned to 
the immediate reduction condition (VLNC) and the normal nicotine 
content (NNC) control condition. We excluded participants in the 
gradual reduction condition because biomarkers of smoke exposure 
were not decreased in this condition relative to the control condition 
in the clinical trial.9
Because menthol flavoring may contribute to cigarette reinforce-
ment,20–23 we hypothesized that the effect of VLNC cigarettes on 
smoking behavior and biomarkers of nicotine and toxicant exposure 
would be smaller in menthol smokers than non-menthol smokers. 
Furthermore, since menthol cigarette smoking is associated with 
poorer cessation outcomes,25–28 we hypothesized that the effect of 
VLNC cigarettes on the odds of being abstinent at the end of the trial 
and the odds of having at least one cigarette-free day during the trial 
would be lower in the participants using menthol cigarettes than in 
participants using non-menthol cigarettes.
Methods
Participants
Adult smokers were recruited from 10 sites across the United States. 
To be eligible, participants had to smoke at least five cigarettes per 
day (CPD), on average, for the past year, have an expired breath 
carbon monoxide (CO) level more than 8 ppm (or urinary cotinine 
level > 1000 ng/ml), and report no intention to quit smoking in the 
next 30 days. Exclusion criteria included recent alcohol use (breath 
alcohol level > 0.02% at screening), a positive urine toxicology test 
(excluding cannabis), unstable medical or psychiatric conditions, 
pregnancy or lactation, use of other tobacco products more than 
9 days in the past 30, exclusive use of roll-your-own cigarettes, and 
prior use of low nicotine content cigarettes during the past 3 years. 
Study procedures were approved by institutional review boards at all 
10 sites, reviewed by the FDA’s Center for Tobacco Products (CTP) 
and the National Institute on Drug Abuse (NIDA), and monitored 
by an external data safety and monitoring board. All participants 
provided written informed consent before enrollment.
Study Design
After completing a 2-week baseline phase during which participants 
smoked their usual brand of cigarettes, participants were randomly 
assigned to a NNC control condition (15.5 mg nicotine/g tobacco), 
an immediate reduction condition (0.4  mg nicotine/g tobacco re-
search cigarettes; VLNC), or a gradual reduction condition (15.5, 
11.7, 5.2, 2.4, and 0.4 mg nicotine/g tobacco; 4 weeks per dose). The 
research cigarettes were provided by NIDA and have been described 
in detail elsewhere.6 For the present analyses, we excluded partici-
pants in the gradual reduction condition. Menthol smoking status 
S65Nicotine & Tobacco Research, 2019, Vol. 21, Suppl. 1
was determined by asking participants if they preferred to receive 
menthol or non-menthol research cigarettes for the duration of the 
20-week intervention.
Participants attended weekly visits between randomization and 
week 4 and then bi-weekly visits from weeks 6–20. At each visit, 
participants received 14- or 28-day supplies of their assigned re-
search cigarettes, free of charge, to allow for any potential changes 
in smoking behavior or to accommodate missed visits. Staff in-
structed the participants to use only their assigned research cigar-
ettes if they smoked but emphasized honest self-report about their 
use of non-study cigarettes. Participants reported—separately—the 
number of study and non-study cigarettes smoked each day using a 
telephone interactive voice response system. During the visits, parti-
cipants completed questionnaires about their tobacco use and sub-
jective responses to the cigarettes and provided biological samples 
(eg, expired breath CO samples; first void urine samples at each 
monthly visit) to assess biomarkers of nicotine and toxicant ex-
posure. To increase compliance with smoking only the study cigar-
ettes, participants were incentivized with a bonus at the end of the 
trial. Participants in the VLNC condition received the bonus if their 
urinary total nicotine equivalents (TNE) levels were ≤ 12 nmol/ml, 
indicating they were mostly compliant with smoking the study cig-
arettes. All participants in the NNC condition received the bonus 
at the end of the trial regardless of their urinary nicotine levels. 
Additional study details have been previously reported.9
Measures
To assess differences between cigarette conditions in smoking be-
havior during the trial, we examined the following outcomes: (1) 
mean total CPD (ie, sum of study and non-study cigarettes) at 
week 20; (2) CO-verified abstinence at week 20 (CO ≤ 5 ppm; for 
the intent-to-treat analysis missing samples were imputed as non-
abstinent [CO > 5 ppm], whereas the per-protocol analysis included 
only participants with CO samples at week 20); (3) any cigarette-
free days during the 20-week trial (yes/no); and (4) mean number of 
cigarette-free days during the 20-week trial.
To measure differences between cigarette conditions on bio-
markers of nicotine and toxicant exposure, we examined the fol-
lowing outcomes: (1) expired breath CO at week 20; (2) urinary 
TNE at week 20; (3) urinary 3-hydroxypropylmercapturic acid 
(3-HPMA) and 2-cyanoethylmercapturic acid (CEMA), metabolites 
of the volatile organic compounds acrolein and acrylonitrile, at week 
20; (4) urinary phenanthrene tetraol (PheT), an indicator of exposure 
to polycyclic aromatic hydrocarbons, at week 20; and (5) urinary 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a metab-
olite for the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), at week 20.
To assess differences between cigarette conditions on changes in 
behavioral and subjective responses to the research cigarettes, we 
examined the following outcomes at week 20: (1) study attrition; (2) 
Minnesota Nicotine Withdrawal Scale (MNWS)29; (3) Questionnaire 
on Smoking Urges - 10 (QSU),30 Factors 1 and 2; (4) modified 
Cigarette Evaluation Questionnaire (mCEQ)31—Satisfaction, 
Psychological Reward, Aversion, Craving Reduction and Enjoyment 
in the Respiratory Tract subscales; and (5) study cigarette com-
pliance, which included only participants in the VLNC condition. 
A urinary TNE criterion of ≤ 6.41 nmol/ml classified participants as 
being compliant with smoking only the VLNC cigarettes.32
Statistical Analyses
For this secondary analysis, we used linear, logistic, and negative bi-
nomial regression to examine whether menthol smoking status mod-
erated the effect of cigarette nicotine content on trial outcomes at 
week 20 in the immediate reduction and normal nicotine control 
conditions. Our primary interest was to compare treatment effects 
(ie, differences between participants randomized to the VLNC and 
NNC groups) by cigarette flavor (menthol vs. non-menthol), which 
was completed by including a nicotine content by cigarette flavor 
interaction term in all regression models. Regression models also in-
cluded the corresponding baseline values of the outcome measure 
(when available), study site, age, race, employment status, educa-
tional attainment, smoking duration, Fagerström Test for Nicotine 
Dependence level, serum nicotine metabolite ratio, and baseline 
values of urine TNE, CPD, and expired CO as covariates. Race, edu-
cational attainment, employment status, CPD, smoking duration, 
CO, and TNE were included in the model because they were signifi-
cantly associated with menthol smoking status at baseline. Other 
covariates were included in the model to be consistent with the ad-
justed analysis reported in the primary manuscript.9
Because menthol smoking status differed by race, we also con-
ducted exploratory analyses within the subset of participants 
identifying as white to minimize potential confounding between race 
and menthol smoking status on responses to VLNC cigarettes. Given 
the small sample size of black non-menthol smokers (n = 22), it was 
not feasible to examine the effects of cigarette nicotine condition in 
black menthol versus non-menthol smokers. A previous smoking ces-
sation trial reported poorer cessation outcomes among white menthol 
smokers relative to white non-menthol smokers,25 so we hypothesized 
that the VLNC cigarette treatment effects would be smaller among 
white menthol smokers relative to white non-menthol smokers. For 
these exploratory analyses, we applied the same statistical approaches 
described earlier but removed race and added gender as a covariate in 
the regression models because gender differed significantly at baseline 
by menthol smoking status among white participants.
TNE, 3-HPMA, CEMA, PheT, and NNAL were natural log-
transformed and analyzed using linear regression; CO-verified ab-
stinence, study attrition, and any cigarette-free days were analyzed 
using logistic regression; number of cigarette-free days was analyzed 
using negative binomial regression; and all other endpoints were 
analyzed using linear regression on the original scale. Tests were 
considered significant at α = 0.05, two-tailed. Because the purpose 
of this study was to explore the potential negative impact of men-
thol flavoring on nicotine reduction outcomes and the parent trial 
was not originally powered to test this interaction, we prioritized 
avoiding Type II error over Type I error. Therefore, we did not cor-
rect for multiple statistical comparisons. Analyses were conducted 
using R statistical software, version 3.3.0.33
Results
Baseline Characteristics by Menthol Smoking Status
Table 1 shows demographic and baseline smoking characteristics in 
the menthol smokers (n = 346) and non-menthol smokers (n = 406). 
At baseline, menthol smokers reported smoking fewer CPD (14.9 
vs. 19.2; p < .01) and had lower TNE (52.8 vs. 71.6 nmol/mg cre-
atinine; p < .01) and CO levels (17.7 vs. 20.5 ppm; p < .01) than 
non-menthol smokers. There were significant differences in menthol 
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smoking status by race such that 90% of black participants smoked 
menthol cigarettes compared to 26% of white participants (p < .01). 
Menthol smokers were also less likely to be employed (38% vs. 
45%; p = .02) and had lower educational attainment (> high school 
education 53% vs. 67%; p < .01) than non-menthol smokers. At 
randomization, participants’ research cigarette flavor selections were 
highly concordant with their self-reported usual brand cigarette 
flavor. Less than 1% of participants opted to receive research cigar-
ettes that differed in flavor from their usual brand cigarette during 
the trial. Five participants preferring menthol usual brand cigarettes 
elected to receive non-menthol research cigarettes whereas four par-
ticipants preferring non-menthol usual brand cigarettes elected to 
receive menthol research cigarettes.
Smoking Behavior
VLNC treatment effects at week 20 by menthol smoking status are 
reported in Table 2, and effects of cigarette nicotine content and 
menthol smoking status on CPD, percent of participants achieving 
abstinence, TNE levels, and CEMA levels are shown in Figure 1. 
At week 20, both menthol and non-menthol smokers in the VLNC 
condition reported significant reductions in the number of cigarettes 
smoked per day relative to participants in the NNC condition, as 
previously reported across both groups.9 The effect of cigarette nico-
tine content on the number of cigarettes smoked per day was signifi-
cantly smaller for participants who smoked menthol cigarettes than 
for those who smoked non-menthol cigarettes (–6.4 vs. –9.3 CPD, 
respectively; p = .04 for the interaction). The odds ratio for the asso-
ciation between cigarette nicotine content and biochemically verified 
abstinence at week 20 was significantly smaller for participants who 
smoked menthol cigarettes than for those who smoked non-menthol 
cigarettes (intent-to-treat odds ratio = 1.88 vs. 9.11, p = .02 for the 
interaction). Both menthol and non-menthol smokers assigned to 
VLNC cigarettes were more likely to report at least one cigarette-
free day and attained more cigarette-free days during the trial than 
those assigned to NNC cigarettes (Table 2), and there were no sig-
nificant interactions between cigarette nicotine content and menthol 
smoking status on these measures.
Biomarkers of Toxicant Exposure
At week 20, both menthol and non-menthol smokers in the VLNC 
condition had significant reductions in urinary TNE and CEMA levels 
relative to participants in the NNC condition, as previously reported 
across both groups.9 The treatment effects were significantly smaller 
for participants who smoked menthol cigarettes compared to parti-
cipants who smoked non-menthol cigarettes for urinary TNE levels 
(ratio of geometric means; 0.22 vs. 0.1, p = .01 for the interaction) and 
urinary CEMA levels (ratio of geometric means; 0.56 vs. 0.37, p = .05 
for the interaction). In addition, there was a trend for a smaller treat-
ment effect on expired breath CO exposure among participants who 
smoked menthol cigarettes relative to those who smoked non-menthol 
cigarettes (–4.5 vs. –7.3 ppm, p = .06 for the interaction). Levels of 
3-HPMA, PheT, and NNAL were lower in the VLNC condition than 
the NNC condition across menthol status conditions, but there were 
no significant interactions between cigarette nicotine content and 
menthol smoking status for these outcomes (Table 2).
Behavioral and Subjective Responses to the 
Research Cigarettes
Study completion rates, QSU craving levels, and positive subjective 
ratings of the study cigarettes were lower in the VLNC condition 
than the NNC condition across menthol status conditions at week 
20 (Table 2), but there were no significant interactions between cigar-
ette nicotine content and menthol smoking status for these outcomes. 
There was a trend for a smaller treatment effect for mCEQ Craving 
Reduction scores at week 20 among participants who smoked men-
thol cigarettes (–1.0 vs. –1.6, p  =  .09) but not for the other four 
mCEQ subscales. In addition, there was no significant interaction for 
the odds of being biochemically verified as compliant with smoking 
only the VLNC cigarettes at week 20 (Supplementary Table 1).
Exploratory Analyses Among White Participants
Supplementary Table 2 provides demographic and smoking charac-
teristics for white menthol and non-menthol smokers. At baseline, 
white menthol smokers (n = 120) were younger (42.8 vs. 45.6 years, 
p = .02), more likely to be female (55% vs. 44%, p = .05), smoked 
fewer CPD (17.4 vs. 19.8, p < .001), had lower TNE (64.1 vs. 
73.3  nmol/mg creatinine, p  =  .03) and had shorter smoking dur-
ations (25.4 vs. 29.3 years, p = .01) than white non-menthol smokers 
(n = 342). VLNC treatment effects among white participants are re-
ported in Table 3. At week 20, white participants who smoked men-
thol cigarettes tended to have lower odds of achieving biochemically 
verified abstinence (OR=1.5 vs. 8.74; p = .07 for the interaction) and 
tended to have smaller mCEQ Craving Reductions scores (–2.4 vs. 
–5.6; p = .07 for the interaction) compared with white participants 
who smoked non-menthol cigarettes, but these interactions were not 
significant (Table 3). No other significant interactions effects were 
observed among white participants at week 20.
Discussion
To date, this is the first VLNC cigarette study to comprehensively 
report the effects of extended VLNC cigarette use on differences in 
smoking behavior, toxicant exposure, and subjective cigarette effects 
by menthol smoking status. Among both menthol and non-menthol 
smokers, participants assigned to the VLNC condition exhibited less 
cigarette smoking and toxicant exposure and were more likely to 
abstain from smoking during the trial, than participants randomized 
to the NNC condition, as previously reported.9 We found significant 
nicotine content by menthol status interactions such that the effect 
of cigarette nicotine content on the number of cigarettes smoked per 
day was smaller for menthol smokers than non-menthol smokers. 
Effects of cigarette condition on biomarkers of nicotine and smoke 
exposure are consistent with the effects on CPD in that menthol 
smokers also experienced smaller reductions in nicotine exposure, 
expired breath CO levels, and levels of urinary CEMA, a biomarker 
for the toxicant and possible carcinogen, acrylonitrile.34 However, 
we did not find significant nicotine content by cigarette flavor inter-
actions for 3-HPMA, PheT, and NNAL, indicating that these risk 
measures were reduced in all smokers assigned to VLNC cigarettes, 
notwithstanding their menthol status.
The most striking interaction observed in this study was the dif-
ference in the effect of cigarette nicotine content on the likelihood of 
being abstinent at week 20. The trial enrolled non-treatment-seeking 
smokers, so this may be a conservative estimate of spontaneous 
quitting at the population level. Yet, the interaction between nicotine 
content and menthol smoking status on abstinence rates indicates 
that the effects of cigarette nicotine reduction on smoking cessa-
tion may be greater in non-menthol smokers than menthol smokers. 
These findings align with prior smoking cessation studies that re-
ported poorer cessation outcomes for menthol smokers compared to 
non-menthol smokers.25–27,35
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In preclinical studies, menthol flavoring has been shown to in-
crease nicotine-self administration.20–23 Therefore, the smaller treat-
ment effects on CPD observed in this study among menthol smokers 
could partially be explained by the potential reinforcing effect of 
menthol flavoring in cigarettes. Alternatively, menthol smokers were 
lower than non-menthol smokers on most outcomes measured at 
baseline, so we cannot rule out the possibility that the smaller treat-
ment effects were due, at least in part, to a baseline-dependent effect36 
(ie, that the amount of change in responding following an interven-
tion is dependent on the baseline rate of behavior). For example, 
although the non-menthol VLNC participants had higher TNE levels 
than the menthol VLNC participants at baseline, both groups ended 
up at approximately the same absolute level of nicotine exposure at 
week 20, suggesting a possible baseline-dependent effect. However, a 
recent VLNC cigarette trial among non-daily smokers reported sig-
nificant reductions in the number of cigarettes smoked per day, des-
pite having low baseline smoking rates,8 indicating a smaller change 
in menthol smokers may be a pharmacological effect of the interven-
tion rather than a baseline-dependent (ie, non-specific) effect.
Menthol and non-menthol smokers reported similar subjective 
responses to the research cigarettes during the 20-week trial. We ob-
served a trend toward an interaction between cigarette nicotine con-
tent and menthol smoking status on the mCEQ Craving Reduction 
subscale, a single-item assessment, suggesting that menthol smokers 
experienced smaller reductions in craving compared to non-menthol 
smokers. However, no significant interactions were detected for the 
QSU, a multi-item assessment of cigarette craving, or on the other 
mCEQ subscales. These findings indicate that VLNC cigarettes were 
similarly effective at reducing cigarette craving and positive subjective 
effects of smoking across menthol status conditions, consistent with 
previous laboratory assessments of VLNC cigarettes comparing sub-
jective smoking outcomes by menthol smoking status.37,38
The results of this study should be considered within the context 
of several limitations. First, menthol smoking status was not ran-
domized. Participants selected whether they wanted to receive men-
thol or non-menthol research cigarettes for the duration of the trial. 
Therefore, unknown or unobserved variables that vary by menthol 
smoking status may have contributed to the differences in treatment 
effects between menthol and non-menthol smokers observed in this 
study. Second, menthol smoking status was confounded by race. In 
the analytic sample (N = 752), only 22 black participants selected 
non-menthol research cigarettes to smoke during the trial, so the 
demographic characteristics of the menthol and non-menthol groups 
differed significantly by race. To address the potential confounding, 
we first adjusted for race and other related covariates in the regres-
sion models. When holding these variables constant, the effects of 
cigarette nicotine content on smoking behavior and biomarkers 
of exposure were smaller for menthol smokers than non-menthol 
smokers. In addition, we conducted separate exploratory analyses 
of menthol status effects among white participants to remove race 
as a potential confounder. Although the interactions were no longer 
statistically significant when the analyses were restricted to white 
participants, the direction of the effects remained consistent with the 
overall sample. Furthermore, these findings align with a large cessa-
tion trial that reported white menthol smokers had poorer abstin-
ence outcomes compared to white non-menthol smokers.25 A third 
limitation is that the trial was not originally powered to detect inter-
action effects of cigarette nicotine content and menthol smoking 
status, especially when the sample is restricted to white smokers. 
Therefore, nonsignificant findings may be partially because of Type 
II error. Finally, compliance to smoking only VLNC cigarettes during 
the trial was moderate, with 39% of participants in the VLNC condi-
tion achieving the compliance criteria at week 20.9 Non-compliance 
in VLNC cigarette trials is problematic because it can lead to under-
estimations of the treatment effects. However, in this study, there 
0
10
20
30
Baseline Week 20
DPC
nae
M
Cigarees Per Day
Non-Menthol NNC Non-Menthol VLNC
Menthol NNC Menthol VLNC
0%
10%
20%
30%
Randomized Completers
%
 o
f P
ar
c
ip
an
ts
CO-Verified Absnence at Week 20
Non-Menthol NNC Non-Menthol VLNC
Menthol NNC Menthol VLNC
0
15
30
45
60
75
Baseline Week 20
)g
m/lo
mn(
nae
Mcirte
moeG
Urinary Total Nicone Equivalents
Non-Menthol NNC Non-Menthol VLNC
Menthol NNC Menthol VLNC
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Baseline Week 20Ge
om
et
ric
 M
ea
n 
(n
m
ol
/m
g) Urinary CEMA
Non-Menthol NNC Non-Menthol VLNC
Menthol NNC Menthol VLNC
A B
C D
Figure 1. Cigarettes per day, abstinence, and urinary biomarkers of exposure.
S70 Nicotine & Tobacco Research, 2019, Vol. 21, Suppl. 1
Ta
b
le
 3
. T
re
at
m
en
t 
E
ff
ec
t 
o
n
 O
u
tc
o
m
es
 a
t W
ee
k 
20
 f
o
r W
h
it
e 
Pa
rt
ic
ip
an
ts
 b
y 
M
en
th
o
l S
m
o
ki
n
g
 S
ta
tu
s
O
ut
co
m
e
In
te
ra
ct
io
n 
te
st
s
M
en
th
ol
 s
m
ok
er
s
N
on
-m
en
th
ol
 s
m
ok
er
s
U
na
dj
us
te
d 
m
od
el
1
A
dj
us
te
d 
m
od
el
2
U
na
dj
us
te
d 
m
od
el
1
A
dj
us
te
d 
m
od
el
2
U
na
dj
us
te
d 
m
od
el
1
A
dj
us
te
d 
m
od
el
2
p 
V
al
ue
p 
V
al
ue
T
re
at
m
en
t 
ef
fe
ct
p 
V
al
ue
T
re
at
m
en
t 
ef
fe
ct
p 
V
al
ue
T
re
at
m
en
t 
ef
fe
ct
p 
V
al
ue
T
re
at
m
en
t 
ef
fe
ct
p 
V
al
ue
To
ta
l C
PD
.4
07
.2
57
–6
.7
 (
–1
0.
7,
 –
2.
7)
.0
01
–6
.1
 (
–1
0,
 –
2.
1)
.0
03
–8
.7
 (
–1
0.
9,
 –
6.
4)
<.
00
1
–8
.7
 (
–1
0.
9,
 –
6.
5)
<.
00
1
A
ny
 c
ig
ar
et
te
-f
re
e 
da
ys
.7
15
.8
52
2.
18
  (
0.
85
, 5
.5
9)
.1
03
2.
55
 (
0.
85
, 7
.6
5)
.0
94
1.
78
 (
1.
03
, 3
.0
7)
.0
37
2.
27
 (
1.
24
, 4
.1
6)
.0
08
M
ea
n 
ci
ga
re
tt
e-
fr
ee
 d
ay
s
.6
69
.2
83
3.
04
  (
0.
76
, 1
2.
26
)
.1
17
2.
14
 (
0.
54
, 8
.4
8)
.2
78
4.
33
 (
1.
93
, 9
.7
)
<.
00
1
5.
05
 (
2.
28
, 1
1.
19
)
<.
00
1
C
O
-v
er
ifi
ed
 a
bs
ti
ne
nc
e 
(p
er
-p
ro
to
co
l)
.2
35
.1
16
2.
78
 (
0.
72
, 1
0.
74
)
.1
39
3.
42
 (
0.
6,
 1
9.
34
)
.1
65
7.
87
 (
2.
73
, 2
2.
73
)
<.
00
1
18
.1
9 
(5
.3
3,
 6
2.
07
)
<.
00
1
C
O
-v
er
ifi
ed
 a
bs
ti
ne
nc
e 
(i
nt
en
t-
to
-t
re
at
)*
.1
97
.0
94
2.
01
 (
0.
54
, 7
.5
5)
.2
99
1.
94
 (
0.
39
, 9
.6
4)
.4
17
6.
12
 (
2.
14
, 1
7.
53
)
.0
01
10
.3
8 
(3
.2
4,
 3
3.
31
)
<.
00
1
C
O
.4
75
.3
39
–4
.8
 (
–8
.9
, –
0.
7)
.0
22
–4
.7
 (
–8
.8
, –
0.
7)
.0
24
–6
.5
 (
–8
.7
, –
4.
3)
<.
00
1
–7
 (
–9
.2
, –
4.
8)
<.
00
1
T
N
E
.9
8
.6
73
0.
11
 (
0.
05
, 0
.2
5)
<.
00
1
0.
13
 (
0.
05
, 0
.2
9)
<.
00
1
0.
11
 (
0.
07
, 0
.1
7)
<.
00
1
0.
1 
(0
.0
6,
 0
.1
6)
<.
00
1
3-
H
PM
A
.5
39
.2
29
0.
76
 (
0.
52
, 1
.1
2)
.1
68
0.
83
 (
0.
56
, 1
.2
1)
.3
28
0.
67
 (
0.
54
, 0
.8
2)
<.
00
1
0.
63
  (
0.
51
, 0
.7
8)
<.
00
1
C
E
M
A
.5
96
.3
06
0.
5 
(0
.2
9,
 0
.8
7)
.0
15
0.
53
 (
0.
31
, 0
.9
1)
.0
21
0.
42
 (
0.
31
, 0
.5
7)
<.
00
1
0.
38
 (
0.
28
, 0
.5
1)
<.
00
1
Ph
eT
.4
53
.5
96
0.
67
 (
0.
5,
 0
.9
1)
.0
1
0.
69
 (
0.
51
, 0
.9
4)
.0
18
0.
77
 (
0.
65
, 0
.9
)
.0
02
0.
76
 (
0.
64
, 0
.8
9)
.0
01
N
N
A
L
.4
24
.5
56
0.
3 
(0
.1
7,
 0
.5
5)
<.
00
1
0.
29
  (
0.
16
, 0
.5
3)
<.
00
1
0.
4 
(0
.2
9,
 0
.5
5)
<.
00
1
0.
36
 (
0.
26
, 0
.4
9)
<.
00
1
C
om
pl
et
er
.9
05
.9
73
0.
46
 (
0.
19
, 1
.1
4)
.0
95
0.
37
 (
0.
13
, 1
.0
3)
.0
58
0.
43
 (
0.
24
, 0
.7
9)
.0
07
0.
38
 (
0.
2,
 0
.7
3)
.0
03
m
C
E
Q
: A
ve
rs
io
n
.6
41
.6
55
0.
2 
(–
0.
1,
 0
.6
)
.2
24
0.
2 
(–
0.
1,
 0
.6
)
.2
19
0.
1 
(–
0.
1,
 0
.3
)
.2
02
0.
1 
(–
0.
1,
 0
.3
)
.1
73
m
C
E
Q
: R
ew
ar
d
.3
35
.7
27
0.
9 
(–
1.
4,
 –
0.
5)
<.
00
1
–0
.8
 (
–1
.3
, –
0.
4)
.0
01
–0
.7
 (
–0
.9
, –
0.
4)
<.
00
1
–0
.8
 (
–1
, –
0.
5)
<.
00
1
m
C
E
Q
: S
at
is
fa
ct
io
n
.0
82
.3
97
–2
.2
 (
–2
.9
, –
1.
6)
<.
00
1
–2
 (
–2
.6
, –
1.
4)
<.
00
1
–1
.6
 (
–1
.9
, –
1.
2)
<.
00
1
–1
.7
 (
–2
, –
1.
4)
<.
00
1
m
C
E
Q
: E
nj
oy
m
en
t
.1
34
.6
39
–1
.6
 (
–2
.2
, –
1)
<.
00
1
–1
.4
 (
–2
, –
0.
8)
<.
00
1
–1
.1
 (
–1
.4
, –
0.
7)
<.
00
1
–1
.2
 (
–1
.6
, –
0.
9)
<.
00
1
m
C
E
Q
: C
ra
vi
ng
.9
78
.7
52
–1
.4
 (
–2
.3
, –
0.
5)
.0
02
–1
.4
 (
–2
.3
, –
0.
4)
.0
04
–1
.4
 (
–1
.9
, –
0.
9)
<.
00
1
–1
.5
 (
–2
, –
1)
<.
00
1
M
N
W
S
.6
6
.5
35
0 
(–
1.
9,
 1
.9
)
.9
84
0.
3 
(–
1.
7,
 2
.3
)
.7
96
–0
.5
 (
–1
.5
, 0
.6
)
.3
77
–0
.5
 (
–1
.6
, 0
.6
)
.4
07
Q
SU
—
Fa
ct
or
 1
.1
86
.0
73
–4
.9
 (
–6
.5
, –
3.
3)
<.
00
1
–2
.4
 (
–5
.4
, 0
.6
)
.1
18
–2
.7
 (
–5
.6
, 0
.3
)
.0
77
–5
.6
 (
–7
.2
, –
3.
9)
<.
00
1
Q
SU
—
Fa
ct
or
 2
.6
66
.4
67
–0
.9
 (
–2
.4
, 0
.6
)
.2
6
–0
.9
 (
–2
.4
, 0
.6
)
.2
51
–1
.3
 (
–2
.1
, –
0.
4)
.0
03
–1
.5
 (
–2
.3
, –
0.
7)
<.
00
1
T
re
at
m
en
t 
ef
fe
ct
s—
di
ff
er
en
ce
 i
n 
m
ea
ns
 f
or
 C
O
, t
ot
al
 C
PD
, m
C
E
Q
 S
at
is
fa
ct
io
n,
 m
C
E
Q
 P
sy
ch
ol
og
ic
al
 R
ew
ar
d,
 m
C
E
Q
 A
ve
rs
io
n,
 m
C
E
Q
 E
nj
oy
m
en
t 
in
 t
he
 R
es
pi
ra
to
ry
 T
ra
ct
, 
m
C
E
Q
 C
ra
vi
ng
 R
ed
uc
ti
on
, 
M
N
W
S,
 Q
SU
 
Fa
ct
or
 1
, Q
SU
 F
ac
to
r 
2,
 a
nd
 n
um
be
r 
of
 c
ig
ar
et
te
-f
re
e 
da
ys
; o
dd
s 
ra
ti
o 
fo
r 
ab
st
in
en
ce
, a
tt
ri
ti
on
, a
nd
 a
ny
 c
ig
ar
et
te
-f
re
e 
da
ys
; r
at
e 
ra
ti
o 
fo
r 
nu
m
be
r 
of
 c
ig
ar
et
te
-f
re
e 
da
ys
; r
at
io
 o
f 
ge
om
et
ri
c 
m
ea
ns
 f
or
 a
ll 
ot
he
r 
ou
tc
om
es
.
1 A
dj
us
ts
 f
or
 b
as
el
in
e 
va
lu
e 
of
 t
he
 o
ut
co
m
e.
2 A
dj
us
ts
 f
or
 b
as
el
in
e 
va
lu
e 
of
 t
he
 o
ut
co
m
e,
 s
tu
dy
 s
it
e,
 a
ge
, r
ac
e,
 e
du
ca
ti
on
al
 a
tt
ai
nm
en
t, 
em
pl
oy
m
en
t 
st
at
us
, F
T
N
D
, s
er
um
 N
M
R
, y
ea
rs
 o
f 
re
gu
la
r 
sm
ok
in
g,
 a
nd
 b
as
el
in
e 
T
N
E
, C
PD
, a
nd
 C
O
. 
*A
ss
um
es
 t
ha
t 
m
is
si
ng
 p
ar
ti
ci
pa
nt
s 
w
er
e 
st
ill
 s
m
ok
in
g 
(i
m
pu
te
d 
C
O
 le
ve
l >
 5
 p
pm
). 
FT
N
D
 =
 F
ag
er
st
rö
m
 T
es
t 
fo
r 
N
ic
ot
in
e 
D
ep
en
de
nc
e.
S71Nicotine & Tobacco Research, 2019, Vol. 21, Suppl. 1
was no significant interaction between cigarette nicotine content and 
menthol smoking status on compliance, bolstering confidence that 
the differences between menthol and non-menthol smokers in this 
trial were not because of different rates of VLNC compliance.
Implications for Tobacco Regulation
Additional tobacco control strategies targeting menthol cigarettes 
could help to augment the public health impact of the proposed 
nicotine reduction policy. In November 2018, the FDA announced 
its renewed interest in banning menthol as a characterizing flavor 
in cigarettes, a policy that has been under consideration for several 
years.39 A  2011 report by the FDA’s Tobacco Products Scientific 
Advisory Committee concluded that menthol cigarettes pose a 
greater public health threat than non-menthol cigarettes, thus ban-
ning menthol as a characterizing flavor in cigarettes could improve 
public health outcomes.40 Importantly, many menthol smokers re-
port they would quit smoking if menthol cigarettes were no longer 
commercially available.41–46 Therefore, a combined policy approach, 
reducing the nicotine content in cigarettes and banning menthol as 
a characterizing flavor, has the potential to maximize public health 
outcomes. A menthol flavor ban for cigarettes could potentially in-
crease motivation to quit and reducing the nicotine content in cig-
arettes could help to facilitate more successful cessation attempts.
Overall, a nicotine reduction policy for cigarettes has the poten-
tial to dramatically shift the tobacco use landscape in the United 
States. Results from this study suggest that both menthol and non-
menthol smokers could benefit from a nicotine reduction policy via 
decreases in smoking behavior and toxicant exposure and increases 
in spontaneous quitting; however, the policy benefits may be greater 
for non-menthol smokers. Implementing a menthol flavor ban con-
currently with a nicotine reduction policy for cigarettes may maxi-
mize the public health benefits of cigarette nicotine reduction for 
menthol smokers.
Supplementary Material
Supplementary data are available at Nicotine and Tobacco Research online.
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